tradingkey.logo

Inhibikase Therapeutics Inc <IKT.OQ> expected to post a loss of 10 cents a share - Earnings Preview

ReutersMay 9, 2025 11:33 PM
  • Inhibikase Therapeutics Inc IKT.OQ IKT.O is expected to show no change in quarterly revenue when it reports results on May 13 (estimated) for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Inhibikase Therapeutics Inc is for a loss of 10 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Inhibikase Therapeutics Inc is $8.00​, above​ its last closing price of $2.00. ​​​

This summary was machine generated May 9 at 23:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI